Literature DB >> 16356477

The candidate tumor suppressor CST6 alters the gene expression profile of human breast carcinoma cells: down-regulation of the potent mitogenic, motogenic, and angiogenic factor autotaxin.

Jin Song1, Chunfa Jie, Paula Polk, Ravi Shridhar, Timothy Clair, Jun Zhang, Lijia Yin, Daniel Keppler.   

Abstract

We recently coined CST6 as a novel candidate tumor suppressor gene for breast cancer. CST6 indeed is expressed in the normal human breast epithelium, but little or not at all in breast carcinomas and breast cancer cell lines. Moreover, ectopic expression of CST6 in human breast cancer cells suppressed cell proliferation, migration, invasion, and orthotopic tumor growth. To obtain insights into the molecular mechanism by which CST6 exhibits its pleiotropic effects on tumor cells, we compared global gene expression profiles in mock- and CST6-transfected human MDA-MB-435S cells. Out of 12,625 transcript species, 61 showed altered expression. These included genes for extracellular matrix components, cytokines, kinases, and phosphatases, as well as several key transcription factors. TaqMan PCR assays were used to confirm the microarray data for 7 out of 11 genes. One down-regulated gene product, secreted autotaxin/lyso-phospholipase D, was of particular interest because its down-regulation by CST6 could explain most of CST6's effect on the breast cancer cells. This study thus provides the first evidence that CST6 plays a role in the modulation of genes, particularly, genes that are highly relevant to breast cancer progression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16356477     DOI: 10.1016/j.bbrc.2005.11.171

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  In Silico Analysis Validates Proteomic Findings of Formalin-fixed Paraffin Embedded Cutaneous Squamous Cell Carcinoma Tissue.

Authors:  Ali Azimi; Kimberley L Kaufman; Marina Ali; Steven Kossard; Pablo Fernandez-Penas
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

Review 2.  Autotaxin (ATX): a multi-functional and multi-modular protein possessing enzymatic lysoPLD activity and matricellular properties.

Authors:  Larra M Yuelling; Babette Fuss
Journal:  Biochim Biophys Acta       Date:  2008-04-29

Review 3.  ATX-LPA receptor axis in inflammation and cancer.

Authors:  Shuying Liu; Mandi Murph; Nattapon Panupinthu; Gordon B Mills
Journal:  Cell Cycle       Date:  2009-11-27       Impact factor: 4.534

4.  Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas.

Authors:  Jingxin Qiu; Lingbao Ai; Cheppail Ramachandran; Bing Yao; Suhasni Gopalakrishnan; C Robert Fields; Amber L Delmas; Lisa M Dyer; Steven J Melnick; Anthony T Yachnis; Philip H Schwartz; Howard A Fine; Kevin D Brown; Keith D Robertson
Journal:  Lab Invest       Date:  2008-07-07       Impact factor: 5.662

Review 5.  Autotaxin.

Authors:  Jean A Boutin; Gilles Ferry
Journal:  Cell Mol Life Sci       Date:  2009-06-09       Impact factor: 9.261

6.  Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions.

Authors:  Ashley G Rivenbark; Chad A Livasy; Courtney E Boyd; Daniel Keppler; William B Coleman
Journal:  Exp Mol Pathol       Date:  2007-04-18       Impact factor: 3.362

7.  Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer.

Authors:  Eunkyung Ko; Seong-Eun Park; Eun Yoon Cho; Yujin Kim; Jung-Ah Hwang; Yeon-Su Lee; Seok Jin Nam; Saik Bang; Joobae Park; Duk-Hwan Kim
Journal:  Breast Cancer Res       Date:  2010-11-23       Impact factor: 6.466

8.  Stat3 mediates expression of autotaxin in breast cancer.

Authors:  Janeen Azare; Ashley Doane; Kenneth Leslie; Qing Chang; Marjan Berishaj; Jennifer Nnoli; Kevin Mark; Hikmat Al-Ahmadie; William Gerald; Maryam Hassimi; Agnes Viale; Mary Stracke; David Lyden; Jacqueline Bromberg
Journal:  PLoS One       Date:  2011-11-28       Impact factor: 3.240

9.  Cystatins in immune system.

Authors:  Spela Magister; Janko Kos
Journal:  J Cancer       Date:  2012-12-20       Impact factor: 4.207

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.